Open randomised controlled trial of inhaled nitric oxide and early dexamethasone in high risk preterm infants

Archives of Disease in Childhood: Fetal and Neonatal Edition

Volumn 77, Issue 3, 1997, Pages

  Subhedar, N V ^a,b   Ryan, S W ^a   Shaw, N J ^b  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b LIVERPOOL WOMEN S HOSPITAL   (United Kingdom)

Author keywords

Chronic lung disease; Dexamethasone; Nitric oxide; Randomised controlled trial

Indexed keywords

DEXAMETHASONE; NITRIC OXIDE;

ARTICLE; CAUSE OF DEATH; CHRONIC LUNG DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; HIGH RISK PATIENT; HUMAN; INCIDENCE; INFANT; LUNG INJURY; NEWBORN; PREMATURITY; PRIORITY JOURNAL; RISK FACTOR; TREATMENT PLANNING;

EID: 0031411595     PISSN: 13592998     EISSN: 14682052     Source Type: Journal    
DOI: 10.1136/fn.77.3.F185     Document Type: Article

References (31)

1. Shaw NJ, Gill AB, Weindling AM, Cooke RW. The changing incidence of chronic lung disease. Health Trends 1993;25:50-3.
2. Abman SH, Kinsella JP. Inhaled nitric oxide therapy of pulmonary hypertension and respiratory failure in premature and term neonates. Adv Pharmacol 1995;34:457-74.
3. Rastogi A, Akintorn SM, Bez ML, Morales P, Pildes RS. A controlled trial of dexamethasone to prevent bronchopulmonary dysplasia in surfactant-treated infants. Pediatrics 1996;98:204-10.
4. Yeh TF, Torre JA, Rastogi A, Anyebuno MA, Pildes RS. Early postnatal dexamethasone therapy in preterm infants with severe respiratory distress syndrome: A double-blind, controlled study. J Pediatr 1990;117:273-82.
5. Roze JC, Storme L, Zupan V, Morville P, Dinh Xuan AT, Mercier JC. Echocardiographic investigation of inhaled nitric oxide in newborn babies with severe hypoxaemia. Lancet 1994; 344:303-5.
6. Collaborative Dexamethasone Trial Group. Dexamethasone therapy in neonatal chronic lung disease: an international placebo-controlled trial. Pediatrics 1991;88:421-7.
7. Sanders RJ, Cox C, Phelps DL, Sinkin RA. Two doses of early intravenous dexamethasone for the prevention of bronchopulmonary dysplasia in babies with respiratory distress syndrome. Pediatr Res 1994;36:122-8.
8. Shinwell ES, Karplus M, Zmora E et al.Failure of early postnatal dexamethasone to prevent chronic lung disease in infants with respiratory distress syndrome. Arch Dis Child 1996;74:F33-7.
9. Ryan SW, Nycyk J, Shaw NJ. Prediction of chronic neonatal lung disease on day 4 of life. Eur J Pediatr 1996;155:668-71.
10. Shennan AT, Dunn MS, Ohlsson A, Lennox K, Hoskins EM. Abnormal pulmonary outcomes in premature infants: prediction from oxygen requirement in the neonatal period. Pediatrics 1988;82:527-32.
11. Iyer P, Evans N. Re-evaluation of the left atrial to aortic root ratio as a marker of patent ductus arteriosus. Arch Dis Child 1994;70:F112-7.
12. Cooke RWI. Early and late cranial ultrasonographic appearances and outcome in very low birthweight infants. Arch Dis Child 1987;62:931-7.
13. The Committee for the Classification of Retinopathy of Prematurity. An international classification of retinopathy of prematurity. Arch Opthalmol 1984;102:1130-4.
14. Finer NN, Etches PC, Kamstra B, Tierney AJ, Peliowski A, Ryan CA. Inhaled nitric oxide in infants referred for extracorporeal membrane oxygenation: dose response. J Pediatr 1994;124:302-8.
15. Buhrer C, Merker G, Falke K, Versmold H, Obladen M. Dose-response to inhaled nitric oxide in acute hypoxemic respiratory failure of newborn infants: a preliminary report. Pediatr Pulmonol 1995;19:291-8.
16. Abman SH, Kinsella JP, Schaffer MS, Wilkening RB. Inhaled nitric oxide in the management of a premature newborn with severe respiratory distress and pulmonary hypertension. Pediatrics 1993;92:606-9.
17. Kinsella JP, Neish SR, Shaffer E, Abman SH. Low-dose inhalation nitric oxide in persistent pulmonary hypertension of the newborn. Lancet 1992;340:819-20.
18. Roberts JD, Polaner DM, Lang P, Zapol WM. Inhaled nitric oxide in persistent pulmonary hypertension of the newborn. Lancet 1992;340:818-9.
19. Barefield ES, Karle VA, Philips JB, Carlo WA. Inhaled nitric oxide in term infants with hypoxaemic respiratory failure. J Pediatr 1996;129:279-86.
20. The Neonatal Inhaled Nitric Oxide Study Group. Inhaled nitric oxide in full-term and nearly full-term infants with hypoxic respiratory failure. N Engl J Med 1997;336:597-604.
21. Roberts JD, Jr, Fineman JR, Morin FC, III, et al. Inhaled nitric oxide and persistent pulmonary hypertension of the newborn. N Engl J Med 1997;336:605-10.
22. Barnes PJ. Nitric oxide and airway disease. Ann Med 1995;27:389-93.
23. Kavanagh BP, Mouchawar A, Goldsmith J, Pearl RG. Effects of inhaled NO and inhibition of endogenous NO synthesis in oxidant-induced acute lung injury. J Appl Physiol 1994;76:1324-9.
24. Kubes P, Granger DN. Nitric oxide modulates microvascular permeability. Am J Physiol 1992;262:H611-5.
25. Haddad IY, Ischiropoulos H, Holm BA, Beckman JS, Baker JR, Matalon S. Mechanisms of peroxynitrite-induced injury to pulmonary surfactants. Am J Physiol 1993;265:L555-64.
26. Mulligan MS, Hevel JM, Marietta MA, Ward PA. Tissue injury caused by deposition of immune complexes is L-arginine dependent. Proc Natl Acad Sci USA 1991;88:6338-6342.
27. Skinner JR, Boys RJ, Hunter S, Hey EN. Pulmonary and systemic arterial pressure in hyaline membrane disease. Arch Dis Child 1991;66:6-11.
28. Evans NJ, Archer LN. Doppler assessment of pulmonary artery pressure and extrapulmonary shunting in the acutephase of hyaline membrane disease.Arch Dis Child 1991;66:6-11.
29. Hogman M, Frostell C, Arnberg H, Sandhagen B, Hedenstierna G. Bleeding time prolongation and NO inhalation. Lancet 1993;341:1664-5.
30. Heal CA, Spencer SA. Methaemoglobinaemia with high-dose nitric oxide administration. Acta Paediatr 1995;84:1318-9.
31. Foubert L, Fleming B, Latimer R, et al. Safety guidelines for use of nitric oxide. Lancet 1992;339:1615-6.